Live Breaking News & Updates on President Worldwide Research

Stay updated with breaking news from President worldwide research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Sachsen Anhalt , Hank Fuchs , Klaus Mohnike , Asia Pacific , Debra Charlesworth , Carmen Alonso Alvarez , Autorisation Temporaire , Traci Mccarty , Health Products Safety , French National Agency For Medicines , European Commission , Drug Administration , Biomarin Pharmaceutical Inc , Exchange Commission , Worldwide Research , Professor Of Paediatrics At Magdeburg University Hospital , Committee For Medicinal Products Human Use , Biomarin Pharmaceutical , Medicinal Products , Human Use , C Type Natriuretic Peptide , Middle East , French National Agency , Temporary Authorization , President Worldwide Research ,

BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study

BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
Children Treated with Vosoritide Demonstrate Cumulative Height Gain of 3.52 cm at Year 2 Compared to Untreated Children
No New Safety Signals Observed
Current Regulatory Review Timelines on Track
News provided by
Share this article
Share this article
SAN RAFAEL, Calif., Dec. 21, 2020 /PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP), maintained an increase in Annual Growth Velocity (AGV) through the second year of continuous treatment. These analyses are the result of the combination of data of the same patients enrolled in three consecutive trials. In the first trial, a run in period consisted of longitudinal measu ....

United States , United Kingdom , City Of , Melita Irving , Hank Fuchs , Asia Pacific , Debra Charlesworth , Traci Mccarty , European Commission , Drug Administration , Biomarin Pharmaceutical Inc , Exchange Commission , Worldwide Research , Prnewswire Biomarin Pharmaceutical Inc , European Medicines Agency , Robust Clinical Program , Committee For Medicinal Products Human Use , Marin Pharmaceutical , C Type Natriuretic Peptide , Annual Growth Velocity , President Worldwide Research , Clinical Geneticist , Evelina London Children , Drug User Fee Act , Medicinal Products , Human Use ,